Abstract
The authors present the AIDS cases (CDC '93) observed in Brescia from 1983 to 1994. They observed 1189 subjects (M 84%, F 16%) with a mean age of 32.7 years (intra-venous drug users 75.1%, heterosexuals 14%, homosexuals 9.6%). The mean survival observed was 56.7 weeks from the diagnosis of AIDS (mortality per year 78%). The most frequent AIDS-defining events were Visceral Candidiasis, P.carinii Pneumonia (PCP) and Neurotoxoplasmosis, while the longest and shortest mean survival was for Kaposi's Sarcoma (89 weeks) and Wasting Syndrome (8.4). The mean value of CD4+ lymphocyte counts on AIDS diagnosis was 72.6/μl (1166 cases) and the highest and lowest were in non-Hodgkin's Lymphoma (NHL; 147.6/μl) and Cryptosporidiosis (18.8/μl). Antiretroviral therapy had been given for at least a month in 41.4% subjects (mean treatment duration of 74.8 weeks). The Cox model has demonstrated the favourable effect on survival of high CD4+ lymphocyte counts on diagnosis, antiretroviral therapy, the diagnosis of Tuberculosis (TBC) and PCP as initial markers and the diagnosis of TBC, PCP or Cytomegalovirus infection (CMV) during the entire clinical evolution. Moreover, the unfavourable effect of high age, diagnosis of Progressive Multifocal Leucoencephalopathy (PML), Wasting Syndrome and NHL as initial markers and diagnosis of PML or NHL in any moment of the disease has been demonstrated.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Batalla J, Gatell JM, Cayla JA, Plascencia A, Jansa JM, Parellada N. Predictors of the survival of AIDS cases in Barcelona — Spain. AIDS 1989; 3: 355–359.
Friedland GH, Saltzman B, Vileno J, Freeman K, Schrager LK, Klein RS. Survival differences in patients with AIDS. J AIDS 1991; 4: 144–153.
D'Arminio-Monforte A, Mainini F, Bini T, et al. Fattori di rischio, patologie diagnostiche e sopravvivenza in una coorte di 547 pazienti affetti da AIDS. Giorn Ital AIDS 1992; 3(2): 85–90.
Fahey IL, Taylor JMG, Detels R, et al. The prognostic value of cellular and serologic markers in infection with Human Immunodeficiency Virus type 1. N Engl J Med 1990; 322(3): 166–72.
Enger C, Graham N, Peng Y, Chmiel JS, Kingsley LA, Detels R, Muñoz A. Survival from early, intermediate and late stages of HIV infection. JAMA 1996; 275: 1329–1334.
Muñoz A, Vlahov D, Solomon L, et al. Prognostic indicators for development of AIDS among intravenous drug users. J AIDS 1992; 5: 694–700.
Kehui L, Matthew L, Kaldor JM, Mc Donald AM, Cooper DA. The role of initial AIDS-defining illness in survival following AIDS. AIDS 1995; 9: 57–63.
Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use and progression of Human Immunodeficiency Virus disease. N Engl J Med 1995; 333(12): 751–756.
Volberding PA, Lagakos SW, Grimes JM, et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA 1994; 272(6): 437–442.
Dorrell L, Snow MH, Ong EL. Mortality and survival trends in patients with AIDS in North-East England from 1984–1992. J Infect 1995; 30(1): 23–27.
Kalbfleisch JD, Prentice RL. The Statistical analysis of failure time data. New York: John Wiley & Sons, 1980.
Pulido F, Peña JM, Rubio R, et al. Survival of HIV infected patients after an episode of Tuberculosis (TB). Is TB always an AIDS event? In: 35th ICAAC, San Francisco 17–20 sett. 1995, Abstr. K 124, 309.
Stein DS, Graham NM, Park LP, Hoover DR, Phair JP, Detels R, Ho M, Saah AJ. The effect of the interaction of acyclovir with zidovudine on progression to AIDS and survival. Analysis of data in the Multicenter AIDS Cohort Study. Ann Intern Med 1994; 121(2): 100–108.
Sabin CA, Phillips AN, Lee CA, Janossy G, Emery V, Griffiths PD. The effect of CMV infection on progression of Human Immunodeficiency virus disease in a cohort of haemophilic men followed up to 13 years from seroconvertion. Epidemiol Infect 1995; 114(2): 361–372.
Ocular Complications of AIDS Research Group, Antiviral effects of Foscarnet and Ganciclovir therapy on Human Immunodeficiency Virus p24 antigen in patients with AIDS and Cytomegalovirus retinitis. J Infect Dis 1995; 172(3): 613–621.
Gallant JE, Moore RD, Keruly J, Richman DD, Chaisson RE. Lack of association between acyclovir use and survival in patients with advanced Human Immunodeficiency Virus disease treated with zidovudine. J Infect Dis 1995; 172(2): 346–352.
Ward JW, Hanson DL, Chu SY, Jones JJ. Survival and trends in anti-retroviral therapy and antimicrobial prophylaxis among persons with 1993–defined AIDS. In: 35th ICAAC, San Francisco 17–20 sett. 1995, Abstr. I 168, 235.
Saravolatz L, Neaton JD, Sacks L, Deyton L, Rhame F, Sherer R. CD4+ T-Lymphocyte counts and patterns of mortality among patients infected with Human Immunodeficiency Virus who were enrolled in community programs for clinical research on AIDS. Clin Infect Dis 1996; 22: 513–520.
Apolonio EG, Hoover DR, He Y, et al. Prognostic factors in Human Immunodeficiency Virus-positive patients with a CD4+ Lymphocyte count < 50/µl. J Infect Dis 1995; 171: 829–836.
Bindels PJE, Krol A, Roos M, Veenstra J, van den Hoek JAR, Miedema F, Coutinho RA. The predictive value of T cell function in vitro and pre-AIDS zidovudine use for survival after AIDS diagnosis in a cohort of homosexual men in Amsterdam. J Infect Dis 1995; 172: 97–104.
Vella S, Giuliano M, Floridia M, et al. Effect of sex, age and transmission category on the progression to AIDS and survival of zidovudine-treated symptomatic patients. AIDS 1995; 9: 51–56.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Casari, S., Donisi, A., Paraninfo, G. et al. Prognostic factors correlated with survival in AIDS patients. Eur J Epidemiol 15, 691–698 (1999). https://doi.org/10.1023/A:1007676625117
Issue Date:
DOI: https://doi.org/10.1023/A:1007676625117